metadoxine
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 23
Of
23
Go to page
1
November 07, 2025
Anti-Inflammatory Drugs for Alcoholic Liver Disease: A Systematic Review on Survival and Adverse Events.
(PubMed, Int J Hepatol)
- "The interventions compared to corticosteroids included pentoxifylline, anakinra, metadoxine, S-adenosylmethionine (SAMe), granulocyte colony-stimulating factor (G-CSF), rifaximin, and fecal microbiota transplantation (FMT) as monotherapies or combination regimens. The evidence is limited by significant study heterogeneity and a lack of high-quality RCTs. These limitations underscore the critical need for well-powered, rigorous RCTs with standardized survival and safety outcomes."
Adverse events • Journal • Review • Hepatology • Inflammation • Transplantation
August 18, 2025
Protective effect of chaige anti-alcoholic granules on acute alcoholic liver injury in rats and acute toxicity in mice.
(PubMed, Front Pharmacol)
- "A rat model of alcoholic liver injury (ALI) was established by gavage of Chinese wine with 56% alcohol, which was intragastrically received with CAG at 1575, 3150 and 6300 mg⋅kg⋅day-1 for 2 weeks, respectively, while positive group 100 mg⋅kg⋅day-1 metadoxine...Liver histological observation showed that CAG could alleviate the infiltration of inflammatory cells. These indicated that CAG had no acute toxicity and exhibited a large safety range, and was first identified to protect against hepatotoxicity through anti-oxidative stress and anti-inflammation, providing a scientific basis for further research into its clinical applications."
Journal • Preclinical • Hepatology • Inflammation • Liver Failure
June 16, 2025
Pharmacological Strategies for the Management of Severe Alcohol-associated Hepatitis: A Systematic Review and Meta-analysis.
(PubMed, Clin Gastroenterol Hepatol)
- "Low certainty evidence supports the efficacy of corticosteroids as first line therapy for eligible patients with severe AH. The certainty of the evidence supporting other therapies ranges from low to moderate. Further studies are needed to confirm these benefits."
Journal • Retrospective data • Review • Acute Kidney Injury • Hepatology • Infectious Disease • Inflammation • Nephrology • Renal Disease • Transplantation
October 30, 2024
Insights into the Binding of Metadoxine with Bovine Serum Albumin: A Multi-Spectroscopic Investigation Combined with Molecular Docking.
(PubMed, Curr Protein Pept Sci)
- "The interactions between metadoxine and bovine serum albumin, cause hyperchromic shift revealed by UV-visible spectroscopy, whereas in Fluorescence spectroscopy, the value of the Stern Volmer constant increases with an increase in temperature, suggesting a stronger interaction between the MD and the BSA, leading to dynamic quenching. Additionally, Fourier-transform infrared and circular dichroism spectroscopy indicated a reduction in the secondary structure of the protein, as evidenced by the shifting of the amide II band and leading to a slight decrease in the αhelix content. The molecular docking shows that metadoxine was docked in the subdomain IIA binding pocket of BSA."
Journal
October 15, 2024
TREATMENT OF ALCOHOL USE DISORDER WITH MEDICATIONS AND WITH INTEGRATED CARE MODEL BENEFIT PATIENTS WITH ALCOHOL-ASSOCIATED LIVER DISEASE
(AASLD 2024)
- "Data from five randomized controlled trials (RCT, n=522) comparing placebo vs. medications for AUD (MAUD, n=347: baclofen in two and one each with fecal matter transplant, metadoxine, and LGG) showed IRR of 0.42 (0.24-0.73). AUD treatment especially with MAUD reduces alcohol relapse and improve patient outcomes. However, this is rarely used with MAUD examined in only 347 patients in clinical trials. An integrated multidisciplinary model reduces alcohol relapse and patient mortality."
Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Hepatology • Liver Failure • Psychiatry
October 04, 2024
Emerging Pharmacologic Treatments for Alcohol-Associated Hepatitis: Current Status and Future Landscape.
(PubMed, Clin Liver Dis)
- "The antioxidants N-acetylcysteine and metadoxine improved survival in large trials. Trials from India report improved survival with granulocyte-colony stimulating factor, as well as improved outcome among patients receiving fecal microbiota transfer. Translational studies suggest that phage treatment of cytolytic Enterococcus faecalis may reduce liver injury."
Journal • Review • Hepatitis C • Hepatology • Inflammation • Liver Failure • IL22
June 25, 2024
Current nonstimulant medications for adults with attention-deficit/hyperactivity disorder.
(PubMed, Expert Rev Neurother)
- "Stimulants, including methylphenidate and amphetamines, are the first-line pharmacological treatment of ADHD in adults...Among other compounds indicated for ADHD in adults, antidepressants sharing at least a noradrenergic or dopaminergic component, including tricyclic compounds, bupropion, and viloxazine, have shown demonstratable efficacy. Evidence is also available for antihypertensives, particularly guanfacine, as well as memantine, metadoxine, and mood stabilizers, while negative findings have emerged for galantamine, antipsychotics, and cannabinoids. While according to clinical guidelines, atomoxetine may serve as the only second-line option in adults with ADHD, several other nonstimulant compounds may be effectively used in order to personalize treatment based on comorbid conditions and ADHD features. Nevertheless, further research is needed to identify and test more personalized treatment strategies for adults with ADHD."
Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry
June 19, 2024
Reduced Pharmacological Intervention of Prehospital Services for Acute Alcohol Intoxication during the COVID-19 Pandemic in A Large District of Southern Italy.
(PubMed, J Clin Med)
- "Metadoxine was administered in almost all alcohol-related emergencies, primarily in conjunction with drugs acting on the gastrointestinal tract, irrespective of age, the period considered, and whether patients were admitted or not admitted to the ED. Conclusions ES is the first and only out-of-hospital service encountered by numerous patients with alcohol-use disorders who refuse to be admitted to the ED. These patients should be directed by ES personnel to a multidisciplinary program to receive treatment for drinking, improve their quality of life, and reduce sanitation costs."
Journal • Addiction (Opioid and Alcohol) • Gastrointestinal Disorder • Infectious Disease • Novel Coronavirus Disease
April 30, 2024
Metadoxine improves alcohol abstinence and is related to a lower risk of decompensation in cirrhosis at a median five-year follow-up: propensity score matching analysis
(EASL-ILC 2024)
- "MTD is effective to improve alcohol abstinence. It is not clear whether the reduction of complications in patients with AC is directly driven by MTD or is indirectly related to abstinence itself."
Acute Kidney Injury • Addiction (Opioid and Alcohol) • CNS Disorders • Fibrosis • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Immunology • Nephrology • Oncology • Psychiatry • Renal Disease • Solid Tumor
April 02, 2024
Metadoxine improves alcohol abstinence and is related to a lower risk of decompensation in cirrhosis at a median five-year follow-up: propensity score matching analysis
(EASL-ILC 2024)
- "MTD is effective to improve alcohol abstinence. It is not clear whether the reduction of complications in patients with AC is directly driven by MTD or is indirectly related to abstinence itself."
Acute Kidney Injury • Addiction (Opioid and Alcohol) • CNS Disorders • Fibrosis • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Immunology • Nephrology • Oncology • Psychiatry • Renal Disease • Solid Tumor
May 10, 2024
Alcohol use disorders and liver fibrosis: an update.
(PubMed, Minerva Med)
- "Treatment drugs include silybin, metadoxine and adenosyl methionine...Other drugs, with promising antifibrotic effects, are now being studied. This review deals with the clinical and pathogenetic aspects of alcohol-related liver fibrosis and suggests possible future strategies to prevent cirrhosis."
Journal • Addiction (Opioid and Alcohol) • Cushing’s Disease • Endocrine Disorders • Fibrosis • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Immunology • Liver Cirrhosis • Oncology • Solid Tumor
March 15, 2024
Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis
(clinicaltrials.gov)
- P3 | N=0 | Withdrawn | Sponsor: Hospital General de Mexico | N=108 ➔ 0 | Trial completion date: Aug 2023 ➔ Mar 2024 | Suspended ➔ Withdrawn | Trial primary completion date: Aug 2023 ➔ Mar 2024
Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis
October 12, 2023
DEVELOPMENT OF ACUTE LIVER FAILURE AND MORTALITY IN PATIENTS WITH DRUG-INDUCED LIVER INJURY: A RISK FACTORS ANALYSIS.
(AASLD 2023)
- "The most frequent DILI causal agents were: antibiotics 35.6%, herbal and dietary supplements (HDS) 29.1%, immunosuppressive agents 7.2%, statins 6.4%, oral antimycotics 5.5%, AINEs 4.5%, carbamazepine 3.6%, anti-tuberculous drugs 2.7%, contraceptives 1.8%, oral dermatological agents 1.8%, antineoplastic 0.9%, valproate 0.9%. Some patients received empirical therapy to treat DILI: 11 (10%) received ursodeoxycholic acid (UDCA), 26 (23.6%) S-adenosylmethionine (SAMe), 25 (22.7%) vitamin E, and 30 (27.3%) metadoxine (MTD)... Antibiotics and HDS were the most frequent agents related to DILI. The hepatocellular injury was related to the development of ALF, and ALF is related to death. No empirical therapy was useful to prevent ALF or death."
Clinical • Cholestasis • Dermatology • Genetic Disorders • Hepatology • Liver Failure • Obesity • Oncology
August 25, 2023
Medications for alcohol use disorder promote abstinence in alcohol-related cirrhosis: results from a systematic review and meta-analysis.
(PubMed, Hepatology)
- "MAUD in patients with cirrhosis are effective in promoting AA and have a good safety profile. Larger studies on the effects of MAUD are needed, especially in patients with advanced liver disease."
Clinical • Journal • Retrospective data • Review • Addiction (Opioid and Alcohol) • Fibrosis • Hepatology • Immunology • Transplantation
July 21, 2023
Lipid nanoparticle delivery of siRNA targeting Cyp2e1 gene attenuates subacute alcoholic liver injury in mice.
(PubMed, Zhejiang Da Xue Xue Bao Yi Xue Ban)
- "The si-Cyp2e1 LNP may attenuate subacute alcoholic liver injury in mice mainly by reducing reactive oxygen levels, increasing antioxidant activity, blocking oxidative stress pathways and reducing ethanol-induced steatosis and inflammation."
Journal • Preclinical • Hepatology • Inflammation • Liver Failure • Metabolic Disorders • CYP2E1 • FASN • IL6 • TGFB1 • TNFA
April 13, 2023
Pharmacological therapy for alcohol use disorder is effective and safe in patients with cirrhosis. Systematic review and meta-analysis
(EASL-ILC 2023)
- "The investigated treatments included baclofen (n=6 studies), metadoxine (n=2), acamprosate (n=2), naltrexone (n=1) and fecal microbiota transplantation (n=1). pharmacological treatment for AUD in patients with cirrhosis increases the probability of AA by 26% and has a good safety profile. Further prospective, high-quality studies are needed to establish a robust recommendation for the use of these treatments in patients with liver disease. Figure: Random-effects model analysis of the relative risk of active alcohol consumption in patients with cirrhosis treated with pharmacological treatments for AUD or control therapy."
Retrospective data • Review • Addiction (Opioid and Alcohol) • Fibrosis • Hepatology • Immunology • Transplantation
March 07, 2023
ADHD-A Clinician's Bird's Eye View of Current Status and New Vistas!
(PubMed, Psychopharmacol Bull)
- "Drugs for ADHD in the pipeline include-dasotraline, armodafinil, tipepidine, edivoxetine, metadoxine, and memantine. Literature on ADHD keeps expanding towards advancing our understanding of the complex and heterogeneous intricacies of this commonplace neurodevelopmental disorder and hence informing better decisions on how best to manage its diverse cognitive, behavioural, social and medical facets."
Journal • Review • ADHD (Impulsive Aggression) • Allergy • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Epilepsy • Genetic Disorders • Immunology • Mood Disorders • Movement Disorders • Obesity • Psychiatry • Sleep Disorder
February 17, 2023
Treatment of acute alcohol intoxication: The role of metadoxine.
(PubMed, Eur J Intern Med)
- No abstract available
Journal
September 30, 2022
Current Medical Treatment for Alcohol-Associated Liver Disease.
(PubMed, J Clin Exp Hepatol)
- "Novel therapies for alcohol-associated hepatitis include metadoxine, interleukin-22 analogs, and interleukin-1-beta antagonists. Finally, granulocyte colony-stimulating factor, microbiota transplantation, and gut-liver axis modulation have shown promising results. We also discuss palliative care in advanced alcohol-associated liver disease."
Journal • Review • Acute Kidney Injury • Addiction (Opioid and Alcohol) • Alcoholic Fatty Liver Disease • CNS Disorders • Endocrine Disorders • Fibrosis • Gastrointestinal Cancer • Hepatic Encephalopathy • Hepatitis B • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Nephrology • Novel Coronavirus Disease • Oncology • Palliative care • Renal Disease • Respiratory Diseases • Sarcopenia • Solid Tumor • Systemic Inflammatory Response Syndrome • Transplantation • IL1B • IL22
August 30, 2022
Progress in the clinical treatment of alcoholic hepatitis
(PubMed, Zhonghua Gan Zang Bing Za Zhi)
- "Corticosteroids remain the mainstay of treatment when patients have a good appetite and normal serum creatinine levels, but early liver transplantation is the only life-saving option for steroid-unresponsive patients. New studies have found that gut microbiota is an important therapeutic targets in patients with alcohol hepatitis, and N-acetylcysteine, granulocyte colony-stimulating factor, and metadoxine as adjunctive therapy have a positive effect on patient survival."
Journal • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Failure • Systemic Inflammatory Response Syndrome • Transplantation
August 24, 2022
Identification and management of acute alcohol intoxication.
(PubMed, Eur J Intern Med)
- "Metadoxine represents a useful drug to increase ethanol metabolism and elimination. Given that AAI could represent a sentinel event of chronic alcohol abuse, patients presenting with acute intoxication should be screened for the presence of an underlying alcohol use disorder and referred to and an alcohol addiction unit to start a multidisciplinary treatment to achieve long term alcohol abstinence. The present review will focus on clinical features, diagnostic criteria and treatment strategies of AAI."
Journal • Review • Addiction (Opioid and Alcohol) • Cardiomyopathy • Cardiovascular • CNS Disorders • Depression • Hepatitis B • Hepatology • Inflammation • Psychiatry • Respiratory Diseases
March 30, 2022
Decidualization-derived cAMP promotes decidual NK cells to be angiogenic phenotype.
(PubMed, Am J Reprod Immunol)
- "These findings suggest that dNK cells display an angiogenic phenotype that can be induced by decidualized cAMP signaling. Our study indicates the significance of decidualization-derived cAMP in regulating angiogenesis of decidual NKs and reveals complex crosstalk between different cell types in a critical period during early pregnancy."
Journal • NCAM1
November 13, 2021
"Metadoxine is missing"
(@hepatologo_RCO)
1 to 23
Of
23
Go to page
1